Brief: BiomX Presents Preclinical Results With BX005 For Atopic Dermatitis
14/06/2021 11:49
June 14 (Reuters) - Biomx Inc PHGE.A :
* BIOMX PRESENTS PRECLINICAL RESULTS WITH BX005 FOR ATOPIC
DERMATITIS AT THE REVOLUTIONIZING ATOPIC DERMATITIS 2021 VIRTUAL
CONFERENCE AND THE INTERNATIONAL CONFERENCE ON PHAGE THERAPY AND
BACTERIOPHAGES
Source text for Eikon: ID:nBw4NXb6ka
Further company coverage: PHGE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tessera Defense and Homeland Security
See all newsBrief: Tessera Defense & Homeland Security - Enters $5 Million Revolving Credit Agreement With Mandragola On Oct 5, 2026 - SEC Filing
Brief: Biomx - Announces One-For-Ten Reverse Stock Split Of Common Stock - SEC Filing
Brief: Biomx And Water.Io Agree To Updated Zorronet Acquisition Terms
Brief: BiomX - May Offer And Sell Up To $9.10 Million Of Common Stock Through Wainwright - SEC Filing
Brief: Biomx Provides Update On Defense Technology Portfolio And Growth Strategy